Details of the Drug Reposition

General Information of This Drug (ID: DMBLHGP)

• Drug Name: Saracatinib (DMBLHGP)
• Synonyms: H8H; AZD-0530; Saracatinib, AZD-0530, AZD0530; N-(5-Chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine
• Therapeutic Class: Anticancer Agents
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

4 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Solid tumour/cancer	DISZR48F	2A00-2F9Z	Phase 2	[1]
Hematologic tumour	DIS9Y1NR	2B33.Y	Phase 2	[1]
Osteosarcoma	DISLQ7E2	2B51	Phase 2	[1]
Metastatic colorectal cancer	DIS18R3K	2B91	Phase 2	[2]

1 Investigative Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Middle East Respiratory Syndrome (MERS)	DIS5VPYU	1D64	Investigative	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7731).
• [2] Phase II Study of Saracatinib (AZD0530) in Patients With Previously Treated Metastatic Colorectal Cancer. Invest New Drugs. 2015 Aug;33(4):977-84.
• [3] Saracatinib Inhibits Middle East Respiratory Syndrome-Coronavirus Replication In Vitro. Viruses. 2018 May 24;10(6). pii: E283.